KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.99

Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.

Joaquim J Ferreira, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Miguel M Fonseca, José-Francisco Rocha, Helena C Brigas, Joerg Holenz, Werner Poewe, Epsilon Study investigators

J Parkinsons Dis 16(4) 797-802

PMID41995421
PMCID-
DOI10.1177/1877718X261436957
发表日期2026-04-17
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

Primary results from the 24-week EPSILON study (NCT04978597) showed that adding opicapone to levodopa in non-fluctuating Parkinson's patients significantly improved motor impairment without increasing the development of motor complications versus placebo. All participants finishing the double-blind phase became eligible for open-label treatment with opicapone. Symptomatic efficacy of opicapone was maintained with 1-year open-label treatment (adjusted-mean ± SE change in MDS-UPDRS motor score from double-blind baseline to Week 76: -7.4 ± 0.81); participants who switched from placebo to opicapone had a motor improvement of -6.1 ± 0.79. At Week 76, 80.2% of opicapone-opicapone-treated participants remained motor complication-free versus 69.7% in the placebo-opicapone group (p = 0.1).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。